GlassScriptPhysician profile
Meng Zhao
NPI 1851385009
$4,814.66
in general payments reported to CMS, 2019-2025
44 companies · $40.56 in 2025
The $40.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $485 · 2021: $871 · 2022: $1,020 · 2023: $909 · 2024: $22.64 · 2025: $40.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.75 | 2019-2024 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $426.91 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $370.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $357.14 | 2020-2023 | Belsomra, Steglatro, Steglujan |
| Lilly USA, LLC | $348.81 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $249.78 | 2019-2023 | Farxiga |
| Abbott Laboratories | $246.96 | 2019-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.31 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $177.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $150.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $147.94 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.24 | 2019-2021 | |
| Amgen INC. | $133.45 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $105.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $99.72 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meng Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.